Long‐Term Outcomes in Seronegative Rheumatoid Arthritis
Arthritis Care & Research · 2026-08 · 78 (8) · 998-1005
DOI: 10.1002/acr.70011 ↗Kurz gefasst
Fachartikel in der Zeitschrift Arthritis Care & Research, online erschienen am 15.03.2026. Verfasst von Bradly A Kimbrough und 7 weiteren Autor:innen. Beteiligte Einrichtung: Mayo Clinic College of Medicine and Science, Rochester, Minnesota. Hauptthemen laut MEDLINE: Arthritis, Rheumatoid, Antirheumatic Agents, Biological Products. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIA NIH HHS, NCATS NIH HHS.
Abstract (Originalsprache)
Objective
The purpose of this study was to determine the cumulative incidence of diagnosis switching, drug‐free remission, and initiation of a biologic or targeted synthetic disease‐modifying antirheumatic drug (b/tsDMARD) in individuals with seronegative rheumatoid arthritis (RA).
Methods
Adult residents of Olmsted County, Minnesota, with incident seronegative (rheumatoid factor negative/anti–cyclic citrullinated peptide antibody negative) RA meeting the 1987 and/or 2010 American College of Rheumatology classification criteria were included. Data were collected from January 1, 2005, to December 31, 2023, through manual chart review. Drug‐free remission was defined as a period of at least six months where the individual was no longer taking treatment for RA and did not have evidence of active inflammatory arthritis upon evaluation by a rheumatologist. We calculated the 10‐year cumulative incidence of a change in diagnosis, adjusting for the competing risk of death, and of drug‐free remission and initiation of a b/tsDMARD, adjusting for the competing risks of death or change in diagnosis.
Results
A total of 176 individuals with seronegative RA (68% women) were included. The 10‐year cumulative incidence of a change in diagnosis was 12.8% (95% confidence interval [CI] 8.7%–18.9%). The most common change in diagnosis was to spondyloarthritis (4%). The 10‐year cumulative incidence of drug‐free remission and initiation of a b/tsDMARD was 26.6% (95% CI 20.7%–34.2%) and 19.9% (95% CI 14.7%–26.9%), respectively. Over a median follow‐up of 11.8 years, 49 individuals entered drug‐free remission.
Conclusion
After initial diagnosis of seronegative RA, about 13% of individuals had a change in diagnosis and a quarter experienced drug‐free remission within 10 years.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Mayo Clinic College of Medicine and Science, Rochester, Minnesota.
ORCID-Profile: Cynthia S Crowson, Vanessa L Kronzer, John M Davis, Elena Myasoedova
Förderung
- NIAMS NIH HHS
- NIA NIH HHS
- NCATS NIH HHS
- National Center for Advancing Translational Sciences
- National Institute on Aging
- National Institute of Arthritis and Musculoskeletal and Skin Diseases
Zitieren
APA
Kimbrough, B. A., George, R. J., Crowson, C. S., Achenbach, S. J., Atkinson, E. J., Kronzer, V. L., Davis, J. M., & Myasoedova, E. (2026). Long‐Term Outcomes in Seronegative Rheumatoid Arthritis. Arthritis Care & Research, 78(8), 998-1005. https://doi.org/10.1002/acr.70011
Vancouver
Kimbrough BA, George RJ, Crowson CS, Achenbach SJ, Atkinson EJ, Kronzer VL, et al. Long‐Term Outcomes in Seronegative Rheumatoid Arthritis. Arthritis Care & Research. 2026;78(8):998-1005. doi:10.1002/acr.70011
BibTeX
@article{Kimbrough2026,
author = {Kimbrough, Bradly A and George, Roslin Jose and Crowson, Cynthia S and Achenbach, Sara J and Atkinson, Elizabeth J and Kronzer, Vanessa L and Davis, John M and Myasoedova, Elena},
title = {Long‐Term Outcomes in Seronegative Rheumatoid Arthritis},
journal = {Arthritis Care & Research},
year = {2026},
volume = {78},
number = {8},
pages = {998--1005},
doi = {10.1002/acr.70011}
}
EUVIMED